Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care
Posted inGastroenterology news Public Health

Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care

A global systematic review (110 cohorts, 50 countries) found substantial attrition across the hepatitis B care cascade: low rates of treatment eligibility assessment and antiviral initiation in primary/community models, poor retention particularly among untreated patients, and only ~73% viral suppression on therapy in specialist settings.
Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
Posted inDiabetes & Endocrinology Nephrology news

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.
Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings
Posted inGastroenterology news Pathology & Lab Medicine

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.
Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: Insights from the Phase 3 GLISTEN Trial and Related Studies
Posted inClinical Updates Gastroenterology news

Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: Insights from the Phase 3 GLISTEN Trial and Related Studies

This review synthesizes evidence from the phase 3 GLISTEN trial and preceding studies on linerixibat, an ileal bile acid transporter inhibitor, demonstrating its efficacy and safety in reducing cholestatic pruritus in primary biliary cholangitis (PBC), and its impact on patient quality of life.
Conservative Dialysis Strategy Accelerates Kidney Recovery in Dialysis-Requiring AKI — Early Randomized Evidence from LIBERATE-D
Posted inCritical Care Nephrology news

Conservative Dialysis Strategy Accelerates Kidney Recovery in Dialysis-Requiring AKI — Early Randomized Evidence from LIBERATE-D

The LIBERATE-D randomized trial found that a conservative, indication-triggered dialysis strategy increased unadjusted kidney-recovery rates at hospital discharge and shortened time to dialysis independence compared with routine thrice-weekly dialysis in patients with dialysis-requiring AKI.
Each Hour Sitting Counts: Sedentary Time Linked to Lower Intrinsic Capacity and Faster Decline in Older Adults
Posted inInternal Medicine news Public Health Rehabilitation Medicine

Each Hour Sitting Counts: Sedentary Time Linked to Lower Intrinsic Capacity and Faster Decline in Older Adults

In a prospective Beijing cohort (BLINDSCE), each additional hour of daily sedentary time was associated with a 1.18-point lower baseline intrinsic capacity and a 0.48-point greater decline over 1 year, suggesting sedentary behavior is a modifiable target to preserve healthy aging.
How Much Aerobic Exercise Is Enough to Reduce Depression in Patients with Chronic Illness? A Dose–Response Meta-analysis Points to an Achievable Target
Posted inInternal Medicine news Psychiatry Rehabilitation Medicine

How Much Aerobic Exercise Is Enough to Reduce Depression in Patients with Chronic Illness? A Dose–Response Meta-analysis Points to an Achievable Target

A meta-analysis of 36 RCTs (n=2,500) found aerobic exercise significantly reduces depressive symptoms in people with chronic illness (Hedges' g -0.73). A weekly dose of ≈405 MET‑min (≈120–135 min of moderate aerobic activity) reaches a minimally important symptom change.